Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial.
The efficacy of chlordiazepoxide and tiapride in the management of acute alcohol withdrawal syndrome was compared in a randomized, parallel-group, double-blind trial. The mean daily dose for both preparations on the first two days was four capsules, i.e., 200 mg for chlordiazepoxide and 400 mg for tiapride. Thereafter the patients were treated according to the relief of symptoms obtained. The treatment periods lasted 3-5 days. Both drugs effectively alleviated alcohol withdrawal symptoms, especially anxiety, fear, hallucinations, insomnia, sweating, tremor, abdominal pain and vertigo. Seventy percent of the patients in the chlordiazepoxide and 42% in the tiapride group considered the drug effective. The difference was statistically significant in favour of chlordiazepoxide (p less than 0.05). Tiapride is an alternative drug in the treatment of this condition, if benzodiazepines are to be avoided.
D000328:Adult; D001549:Benzamides / Q000627:therapeutic use*; D002707:Chlordiazepoxide / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D000431:Ethanol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D013976:Tiapamil Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*
D001549:Benzamides; D000431:Ethanol; D002707:Chlordiazepoxide; D013976:Tiapamil Hydrochloride